Thursday, October 24, 2019 4:49:00 PM
It was an open label, PhI trial, and 17 patients (under the age of 25) with advanced, high-risk CD19+ ALL were enrolled. Fourteen patients received lymphodepletion followed by the infusion of CAR T-cells (the product couldn't be generated for the remaining three).
Thirteen out of 14 patients developed cytokine release syndrome, which was generally mild (nine patients with Gr1, and four with Gr2). No severe (Gr3 or above) CRS was observed. Six had Gr1/2 neurotoxicity and one experienced Gr4 encephalopathy. One developed prolonged neutropenia, multiple infections, and Gr4 encephalopathy, and died from sepsis while in remission. Thirteen out of 14 patients developed prolonged B-cell aplasia.
At 30 days post infusion, 10 achieved a complete response. At 90 days, 12 of 14 had achieved a CR, one was alive with CD19+ disease, and one died due to progression of CD19+ disease. Six who achieved CR ultimately relapsed: 5 with CD19- and 1 with CD19+. In cases of CD19+ relapse/non-responding disease, anti-CAR-specific cytotoxic responses were detected, suggesting endogenous T-cell mediated rejection of CAR T-cells (not good). At a median follow-up of 14 months, 5 out of 14 (36%) patients remained in CR. Overall survival was 84% at 6 months and 63% at 12 months. Event-free survival was 63% and 46% at 6 and 12 months, respectively.
CAR T-cells exhibited mostly naive or central memory phenotypes and had a low level expression of PD-1 and TIM3. CAR T-cells underwent robust expansion in the periphery in 12 out of 14 patients, with a median time to peak expansion of 14 days. At peak expansion, a median of 41% of circulating T-cells were CAR T-cells. CAR T-cells contracted over time, but remained detectable in 11 out of 14 patients at last follow-up (up to 24 months for some patients). The median duration of persistence of CAR T-cells at data cutoff was 215 days. Peak expansion, exposure, persistence, and half-life were all higher than published data for an approved product.
Recent AUTL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 12:09:53 PM
- Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer • GlobeNewswire Inc. • 09/19/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 09:02:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 01:08:31 PM
- Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024 • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:21:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:27:52 PM
- Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 • GlobeNewswire Inc. • 07/26/2024 11:00:00 AM
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:35:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:46 PM
- Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO • GlobeNewswire Inc. • 05/31/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/17/2024 08:39:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 12:27:03 PM
- Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 05/17/2024 11:00:00 AM
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress • GlobeNewswire Inc. • 05/14/2024 02:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/13/2024 01:33:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:23:04 AM
- Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO • GlobeNewswire Inc. • 04/24/2024 02:00:00 PM
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/23/2024 11:00:00 AM
- Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Autolus Therapeutics Announces Changes to its Board of Directors • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates • GlobeNewswire Inc. • 03/14/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM